ReportAn aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients
Section snippets
Methods
The two identical studies (A and B) received approval before patient enrollment from the appropriate institutional review board for each center. They were conducted in accordance with the Declaration of Helsinki and Good Clinical Practices and in compliance with local regulatory requirements. All patients provided written informed consent before entering the studies.
Baseline characteristics
Studies A and B were identical in design and the combined data from these two studies are reported. A total of 2813 patients were enrolled across 68 investigative sites and randomly assigned to one of 4 study drug treatments: clindamycin-BPO 2.5% gel (n = 797); clindamycin phosphate 1.2% gel (n = 812); BPO 2.5% gel (n = 809); or vehicle gel (n = 395).
Demographic data (Table II) were not statistically different across all 4 treatment groups. Mean age across treatment groups was 19.3 years. There
Discussion
BPO is a safe and effective agent for treating acne. Its efficacy is maintained over many years of use with the distinct advantage of not being associated with antimicrobial resistance.2 It has been shown that lower concentrations of BPO (2.5%) can be equally efficacious to higher concentrations of BPO in reducing acne lesions.6 Importantly, the lower concentrations of BPO have reduced cutaneous side effects such as burning, erythema, and peeling.6 It is also well established that products that
Conclusions
The fixed combination of clindamycin phosphate 1.2% and BPO 2.5% in clindamycin-BPO 2.5% aqueous gel is an effective, safe, and well-tolerated topical therapy for the treatment of patients with moderate to severe inflammatory and noninflammatory acne vulgaris.
References (12)
Recent findings in the epidemiologic evidence, classification and subtypes of acne vulgaris
J Am Acad Dermatol
(1998)- et al.
A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris
Clin Ther
(2002) - et al.
Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide and vehicle gel: combined results of two double-blind investigations
J Am Acad Dermatol
(1997) - et al.
Management of acne: a report from the alliance to improve outcomes in acne
J Am Acad Dermatol
(2003) - et al.
Suppression of polymorphonuclear leucocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin
Antimicrob Agents Chemother
(1982) - et al.
A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face
J Cutan Med Surg
(2003)
Cited by (118)
Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials
2023, Journal of the American Academy of DermatologyAn update on formulation strategies of benzoyl peroxide in efficient acne therapy with special focus on minimizing undesired effects
2020, International Journal of PharmaceuticsTopical Antibacterial Agents
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionAcne Vulgaris and Acne Rosacea
2018, Integrative Medicine: Fourth EditionImpact of Topical Vehicles and Cutaneous Delivery Technologies on Patient Adherence and Treatment Outcomes in Acne and Rosacea
2023, Journal of Clinical and Aesthetic Dermatology
Supported by Arcutis Pharmaceuticals.
Disclosure: Dr Thiboutot has been an investigator, consultant, or advisory board member for Allergan Inc, Arcutis Inc, Dusa Inc, Galderma Inc, Stiefel Inc, QLT Inc, and Medicis Inc, and has received honoraria or grant support. Dr Zaenglein has served as an advisory board member for Sanofi Aventis Inc, a speaker for Galderma Inc, an investigator for Arcutis Inc, and has received honoraria or grant support. Dr Weiss has served as an investigator and consultant for Arcutis Inc and has received grant support. Dr Webster has served as an investigator and consultant for Arcutis Inc, a consultant for Allergan Inc, Stiefel Inc, Sanofi Aventis Inc, Dusa Inc, Medicis Inc, Ortho Inc, QLT Inc, Galderma Inc, Coria Inc, Cutanea Inc, and has received honoraria or grant support. Mr Calvarese is an employee of Dow Pharmaceutical Sciences, Inc. Dr Chen is an employee of Arcutis Pharmaceuticals.